OncoMatch/Clinical Trials/NCT07111832
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Is NCT07111832 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-A1811 for and SHR-1316 for pd-l1-positive locally recurrent unresectable or metastatic triple-negative breast cancer.
Treatment: SHR-A1811 for · SHR-1316 · Toripalimab · Paclitaxel for — This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: anti-tumor treatment
Exception: within 4 weeks before the first dose
Have undergone other anti-tumor treatment within 4 weeks before the first dose
Lab requirements
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify